Compare TZOO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TZOO | NTHI |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 114.6M |
| IPO Year | 2003 | N/A |
| Metric | TZOO | NTHI |
|---|---|---|
| Price | $11.66 | $4.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.50 | $15.00 |
| AVG Volume (30 Days) | ★ 136.0K | 91.7K |
| Earning Date | 04-23-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | $50.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $3.71 |
| 52 Week High | $14.05 | $12.99 |
| Indicator | TZOO | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 42.13 |
| Support Level | $9.63 | $4.17 |
| Resistance Level | $11.98 | $5.78 |
| Average True Range (ATR) | 0.69 | 0.48 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 68.53 | 14.73 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.